Long-term outcomes in patients aged ≥70 years with intravenous glyburide from the Phase II GAMES-RP study of large hemispheric infarction an exploratory analysis

Kevin N. Sheth, Nils H. Petersen, Ken Cheung, Jordan J. Elm, Holly E. Hinson, Bradley J. Molyneaux, Lauren A. Beslow, Gordon K. Sze, J. Marc Simard, W. Taylor Kimberly

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Background and Purpose-We aimed to determine whether subjects aged ≥70 years who were treated with intravenous glyburide (RP-1127; BIIB093; glibenclamide) would have better long-term outcomes than those who received placebo. Methods-GAMES-RP (Glyburide Advantage in Malignant Edema and Stroke-Remedy Pharmaceuticals) was a prospective, double-blind, randomized, placebo-controlled phase 2 clinical trial. Eighty-six participants, aged 18 to 80 years, who presented to 18 centers with large hemispheric infarction (baseline diffusion-weighted imaging volumes, 82-300 cm3) randomized within 10 hours of symptom onset were enrolled. In the current exploratory analysis, we included participants aged ≥70 years treated with intravenous glyburide (n=35) or placebo (n=30) who met per-protocol criteria. Intravenous glyburide or placebo was administered in a 1:1 ratio. We analyzed 90-day and 12-month mortality, functional outcome (modified Rankin Scale, Barthel Index), and quality of life (EuroQol group 5-dimension). Additional outcomes assessed included blood-brain barrier injury (MMP-9 [matrix metalloproteinase 9]) and cerebral edema (brain midline shift). Results-Participants ≥70 years of age treated with intravenous glyburide had lower mortality at all time points (logrank for survival hazards ratio, 0.34; P=0.04). After adjustment for age, the difference in functional outcome (modified Rankin Scale) demonstrated a trend toward benefit for intravenous glyburide-treated subjects at 90 days (odds ratio, 2.31; P=0.07). Repeated measures analysis at 90 days, 6 months, and 12 months using generalized estimating equations showed a significant treatment effect of intravenous glyburide on the Barthel Index (P=0.03) and EuroQol group 5-dimension (P=0.05). Participants treated with intravenous glyburide had lower plasma levels of MMP-9 (189 versus 376 ng/mL; P<0.001) and decreased midline shift (4.7 versus 9 mm; P<0.001) compared with participants who received placebo. Conclusions-In this exploratory analysis, participants ≥70 years of age with large hemispheric infarction have improved survival after acute therapy with intravenous glyburide.

Original languageEnglish (US)
Pages (from-to)1457-1463
Number of pages7
Issue number6
StatePublished - 2018


  • brain edema
  • glyburide
  • infarction
  • ischemic stroke
  • malignant infarction

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing


Dive into the research topics of 'Long-term outcomes in patients aged ≥70 years with intravenous glyburide from the Phase II GAMES-RP study of large hemispheric infarction an exploratory analysis'. Together they form a unique fingerprint.

Cite this